We want you to be involved in our work. Tell us what matters to you, your organisation or your community.
If you want to stay up-to-date with what we're currently doing, and help develop our products, you could register as a NICE stakeholder.
All guidelines and quality standards are open for consultation during their development. Registered stakeholders can comment on our recommendations.
Our guidance and quality standards are all developed by independent committees. Join and have an active role in producing a guideline or quality standard.
Advisory committee meetings, technology appraisal appeal hearings, public board meetings and some of our other meetings are open to the public and press. Come along and see how we work.
NICE Listens is a new programme of public engagement. It's been developed to give us an understanding of public opinion on moral, ethical and social value issues.
Speak to our team for more detailed information on our public involvement programme.
Join our adoption and impact panel to give expert advice on tools and resources developed to support NICE guidance.
Are you a doctor, non-medical prescriber or pharmacist? Our network of medicines and prescribing associates help us to support high quality, safe, cost-effective prescribing and medicines optimisation.
We have lots of opportunities to join our friendly and busy teams. Take a look at our current vacancies and see how you can contribute to shaping the future of health and social care.
Join our insight community and help influence the development and improvement of our products.
Find out about events we're hosting or attending, such as conferences and seminars. You can also request a speaker for your event by completing a short form.
Find out about the Executive MSc in Evaluation of Health Care Interventions and Outcomes. This is a master's degree we co-developed with the London School of Economics and Political Science (LSE).
We’ve created an early prototype for how our Type 2 diabetes in adults: management guideline could look in the future, and we’d like to know what you think of it.